What is studied and why does this matter
The record describes a trial focused on a dietary supplement blend that combines amylopectin with chromium. The goal is to assess its effect on whole body protein metabolism and on glucose control in a population that includes perimenopausal and postmenopausal women. This is a relevant area because metabolic regulation and protein turnover can change with age and hormonal status. Continuous glucose monitoring is used to capture glucose patterns over time and to provide data that reflect daily living conditions. A placebo control is included to create a comparison against the active blend, supporting a regulatory critical assessment of any potential product effects. The sponsors named are Nutrition 21 Inc and The Center for Applied Health Sciences LLC. The record indicates that the study is actively recruiting and that more details are available on the official trial page.
How is the trial designed and who is eligible
Interventions described include two active arms using the amylopectin chromium blend and a placebo arm. The summary does not specify a randomization method or blinding in detail. The population includes perimenopausal and postmenopausal women who meet predefined criteria. This design aligns with a controlled evaluation of a dietary supplement in a defined group and seeks to isolate metabolic effects related to the blend and to glucose management. Sponsors are listed and the recruitment status remains active, highlighting ongoing data collection.
What interventions are used and how are outcomes measured
Active interventions involve the amylopectin chromium blend provided as a dietary supplement. A second active arm is described using the same blend, while a placebo arm serves as a comparator. Outcomes rely on continuous glucose monitoring to capture glucose trends and on measures of whole body protein metabolism. The approach reflects a structured data collection plan intended to support evaluation of safety and performance in a trial context. The text references the trial setting and the need for regulatory oversight in evaluating a dietary supplement in this population.
What is the status and where can I find more information
The record shows recruitment for the study and lists the named sponsors. For official information the public can review the ClinicalTrials.gov record linked below. The page provides details on eligibility criteria, interventions and study timelines as described in the record. The external link is provided as the primary source for status updates and protocol specifics.
ClinicalTrials.gov record: https://clinicaltrials.gov/study/NCT07402382?term=medical+device
What regulatory considerations apply
In this update the focus is on how the trial aligns with regulatory expectations for a product described as a dietary supplement evaluated in a clinical context. The described intended purpose is to gather evidence on metabolic parameters and safety in a defined population. The record frames performance and safety as part of a trial context rather than a marketed product claim. The sponsors and the design are described to support risk management and future labeling decisions under regulatory review.
What are the timelines and implications
Recruitment status indicates ongoing enrollment. The outcomes from this trial could inform future regulatory discussions about labeling and safety monitoring for a chromium blend used in a perimenopausal and postmenopausal group. Stakeholders should monitor updates from sponsor organizations and from the ClinicalTrials.gov record for changes in status or results as they become available. The information may influence how similar products are evaluated in the regulatory environment and in post market oversight if the product progresses beyond the trial stage.
FAQ
- 1. What is the focus of this study and who is included
- 2. Who funds the research and who conducts it
- 3. Where can the official information be found
- 4. Does this imply a final product claim
Conclusion and implications for stakeholders
The record describes a controlled evaluation of an amylopectin chromium blend in a defined female population. It uses continuous glucose monitoring and protein metabolism assessments to build evidence in a regulatory context. The sponsor names and the recruiting status indicate ongoing activity and a public record for oversight. Given the regulatory emphasis on safety and performance in a trial setting, professionals should monitor the ClinicalTrials.gov entry for updates on results and status and consider how the evidence might influence future labeling and risk management for similar dietary supplements.
Disclaimer This summary is for professional readers and is not legal advice. It should not replace regulatory counsel or formal guidance.
https://clinicaltrials.gov/study/NCT07402382?term=medical+device